ZHONGSHENGYAOYE(SZ:002317) Ge Long Hui·2025-11-23 08:00Core Viewpoint - The company has successfully completed the first participant enrollment and dosing for the Phase III clinical trial of the innovative drug Angladevir granules, aimed at treating uncomplicated influenza A in children aged 2 to 11 years [1][2]. Group 1: Product Development - Angladevir tablets (brand name: Anruiwei) is the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, approved for adult patients with uncomplicated influenza A, featuring rapid, potent, and low-resistance characteristics, and is set to be launched in May 2025 [1]. - The company is also conducting a Phase III clinical trial for Angladevir tablets to treat adolescents aged 12 to 17 years with uncomplicated influenza A, with participant enrollment progressing smoothly under the guidance of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine [1]. Group 2: Clinical Trial Progress - The Phase II clinical trial results for Angladevir granules showed positive efficacy and good safety, leading to the initiation of the Phase III clinical trial, which has now completed the first participant enrollment and dosing under the guidance of Beijing Children's Hospital affiliated with Capital Medical University [2]. - The company is committed to advancing both Phase III clinical trials with high quality, speed, and scientific rigor [2].